Dashboard
Manage Tickers

IMAB NovaBridge Biosciences.


$ 4.20 $ -0.34 (-7.51 %)    

Thursday, 20-Nov-2025 15:59:11 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 585.30 $ -14.20 (-2.37 %)
DIA $ 458.06 $ -3.66 (-0.79 %)
SPY $ 652.20 $ -10.10 (-1.52 %)
TLT $ 89.25 $ 0.35 (0.39 %)
GLD $ 374.75 $ -0.11 (-0.03 %)
$ 4.19
$ 4.59
$ 4.20 x 227
$ 4.22 x 412
$ 4.15 - $ 4.70
$ 0.60 - $ 6.79
741,502
na
na
$ 1.49
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

i-mab-changes-name-to-novabridge-biosciences-to-trade-under-new-name-nbp-ticker-effective-oct-30
I-Mab Changes Name To NovaBridge Bioscienc...
10/29/2025 13:20:09

NovaBridge Biosciences (NovaBridge or the Company) today announced that it has changed its corporate name from I-Mab to NovaBri...

btig-reiterates-buy-on-i-mab-maintains-9-price-target
BTIG Reiterates Buy on I-MAB, Maintains $9...
10/24/2025 09:44:18

BTIG analyst Justin Zelin reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $9 price target.

i-mab-reports-18-response-rate-for-givastomig-monotherapy-in-heavily-pretreated-gastric-cancer-phase-2-trial-to-launch-in-2026-to-present-data-at-2025-aacr-nci-eortc-molecular-targets-and-cancer-therapeutics-conference-on-october-23-2025
I-Mab Reports 18% Response Rate For Givast...
10/22/2025 16:49:07

Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received a...

btig-maintains-buy-on-i-mab-raises-price-target-to-9
BTIG Maintains Buy on I-MAB, Raises Price ...
10/17/2025 18:19:26

BTIG analyst Justin Zelin maintains I-MAB (NASDAQ:IMAB) with a Buy and raises the price target from $7 to $9.

trading-halt-halt-status-updated-at-42000-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 4:20:...
10/16/2025 20:20:04

i-mab-laucnhes-new-business-model-focused-on-leveraging-its-global-capabilities-to-accelerate-access-to-innovative-medicines-and-drive-strategic-growth-company-plans-a-dual-listing-ipo-in-hong-kong-and-nasdaq-and-will-operate-under-the-new-name-novabridge-biosciences
I-Mab Laucnhes New Business Model Focused ...
10/16/2025 20:08:11

New business model reflects strategic transition to a global biotech platform focused on business development and translational...

trading-halt-halted-at-40100-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:01:00 p.m. ET - ...
10/16/2025 20:01:04

i-mab-to-present-updated-phase-1-givastomig-data-in-gastroesophageal-cancer-at-major-oncology-conference
I-Mab to Present Updated Phase 1 Givastomi...
10/14/2025 11:10:01

I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncolog...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/13/2025 17:06:02

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/10/2025 21:06:24

dell-select-medical-century-aluminum-and-other-big-stocks-moving-higher-on-wednesday
Dell, Select Medical, Century Aluminum And...
10/08/2025 14:39:06

this-bank-of-new-york-mellon-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This Bank of New York Mellon Analyst Begin...
10/03/2025 13:01:13

leerink-partners-initiates-coverage-on-i-mab-with-outperform-rating-announces-price-target-of-9
Leerink Partners Initiates Coverage On I-M...
10/03/2025 10:55:04

Leerink Partners analyst Daina Graybosch initiates coverage on I-MAB (NASDAQ:IMAB) with a Outperform rating and announces Pr...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 12:09:34

why-wolfspeed-shares-are-trading-higher-by-over-50-here-are-20-stocks-moving-premarket
Why Wolfspeed Shares Are Trading Higher By...
09/30/2025 09:37:13

btig-reiterates-buy-on-i-mab-maintains-7-price-target
BTIG Reiterates Buy on I-MAB, Maintains $7...
09/10/2025 17:15:08

BTIG analyst Justin Zelin reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $7 price target.

btig-initiates-coverage-on-i-mab-with-buy-rating-announces-price-target-of-7
BTIG Initiates Coverage On I-MAB with Buy ...
09/09/2025 10:38:38

BTIG analyst Justin Zelin initiates coverage on I-MAB (NASDAQ:IMAB) with a Buy rating and announces Price Target of $7.

needham-reiterates-buy-on-i-mab-maintains-6-price-target
Needham Reiterates Buy on I-MAB, Maintains...
09/08/2025 15:50:03

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

i-mab-accelerates-givastomig-development-with-global-phase-2-trial-in-metastatic-gastric-cancer-expands-pipeline-and-appoints-wei-fu-as-executive-chairman
I-Mab Accelerates Givastomig Development W...
09/08/2025 12:39:58

Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in ...

c3ai-posts-downbeat-results-joins-gitlab-salesforce-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
C3.ai Posts Downbeat Results, Joins GitLab...
09/04/2025 12:17:31

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION